Megiorni Francesca, Pizzuti Antonio, Frati Luigi
Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena, 324-00161 Rome, Italy.
Patholog Res Int. 2011;2011:780652. doi: 10.4061/2011/780652. Epub 2011 Jul 27.
Lung cancers account for a huge percentage of death in industrialized countries, and hence there is an increasing call for the development of novel treatments. These malignancies are caused by a combination of environmental factors, principally cigarette smoking and genetic alterations. MicroRNAs (miRNAs) are a recently discovered class of regulatory noncoding small RNAs with a significance in numerous biological processes. Strong evidence links miRNA impaired expression profiles and pathways to the etiology of several diseases, including neoplasia. This paper focuses on the emerging role of miRNA function in lung cancer development with particular highlighting on the use of miRNA profiles and polymorphisms for the molecular and biological characterization of tumor pulmonary growth and progression. Furthermore, we underline the potential utility of lung cancer-associated miRNAs as clinical biomarkers with a diagnostic, prognostic, and therapeutic significance and give emphasis to the promising novel miRNA-based curative strategies.
在工业化国家,肺癌导致的死亡占比巨大,因此对新型治疗方法的需求日益增加。这些恶性肿瘤是由环境因素(主要是吸烟)和基因改变共同引起的。微小RNA(miRNA)是最近发现的一类具有调控作用的非编码小RNA,在众多生物过程中具有重要意义。有力证据表明,miRNA表达谱和通路受损与包括肿瘤形成在内的多种疾病的病因有关。本文重点关注miRNA功能在肺癌发展中的新作用,特别强调利用miRNA谱和多态性对肺部肿瘤生长和进展进行分子和生物学特征分析。此外,我们强调与肺癌相关的miRNA作为具有诊断、预后和治疗意义的临床生物标志物的潜在用途,并着重介绍基于miRNA的有前景的新型治疗策略。